Directors

Prof J Gordon McVie MD, FRCP, FRCPS, FRCES, FMedSci, DSc (Hon)

is non- executive Chairman of the Board and Chairman of ORIL’s Scientific Advisory Committee. Professor McVie was formerly Director General of the Cancer Research Campaign in the UK before it merged with the Imperial Cancer Research Foundation to form Cancer research UK, when he became co-Director General. Professor McVie is a leading world authority in the research and treatment of cancer, having trialled over 80 new chemical entities in the clinic.

Professor McVie is currently Senior Consultant at the Scientific Directorate within the European Institute of Oncology, Milan and Director of Cancer Intelligence, which provides advisory services to biotechnology and pharmaceutical companies, investors, the media and cancer patients. He is visiting professor at Glasgow University and honorary consultant in medical oncology at the Welsh Cancer Institute, Cardiff.

Dr Philip A Marshall BSc(Hons), PhD, FRACI, CChem, MAICD

is Chief Executive Officer and Director. Dr Marshall manages the corporate aspects of the Company, as well as the scientific and research programs. Dr Marshall has 30 years’ international experience at senior and executive management level in scientific affairs within the pharmaceutical industry. He has considerable experience in bringing products from concept to commercialisation, risk management, compliance to best practice and international regulatory affairs, due diligence and in patents.

Dr Marshall’s skills and training cover synthetic organic and medicinal chemistry, pharmaceutical science, compliance and regulatory affairs. In 1991 he founded his consultancy company, Pharmchem Technical Services Pty Ltd, which has provided independent advice to over 130 companies in Europe, South Africa, the Americas and throughout Asia-Pacific. From 2004-06, he was also General Manager, Scientific Affairs at Sigma Pharmaceuticals, where he had executive responsibility over the company’s 6 Australian sites for R&D strategic planning, quality, regulatory affairs and technical due diligence in acquisitions, whilst overseeing 180 scientific staff. Dr Marshall is also a member of the Australian Institute of Company Directors.

Dr K Michael Wayte

is Company Secretary and Director. Dr Wayte was full time CEO of ORIL from 2003 to 2008 and is a major shareholder. He was diagnosed with bowel cancer in 1986. After following a demanding and restrictive vegetarian diet with specific plant-based therapies he recovered and is alive and well today. As a result of his recovery he founded ORIL in 1993 with the objective of researching plant-based therapies for cancer.

Mr Peter Fallon (Adviser to board)

is a chartered accountant and principal at Crowe Horwath, where he heads the highly specialised Tax Consulting Division. Mr Fallon has over twenty five years experience in professional practice and has extensive practical experience in all aspects of corporate taxation, specialising in corporate reorganisation, capital gains tax and goods and services tax. He advises corporate clients in all aspects of tax law, including demergers, takeovers, tax consolidation, due diligence, international tax planning and business sale transactions. He has also developed a Business Planning process to assist businesses cope with the ever-increasing challenges.